Mesoblast Competitors
| MESO Stock | USD 15.95 0.13 0.81% |
Mesoblast vs Cogent Biosciences Correlation
Very weak diversification
The correlation between Mesoblast and COGT is 0.49 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Mesoblast and COGT in the same portfolio, assuming nothing else is changed.
Moving together with Mesoblast Stock
Moving against Mesoblast Stock
| 0.7 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.57 | EVGN | Evogene | PairCorr |
| 0.5 | GNLX | Genelux Common | PairCorr |
| 0.44 | JUMP | Leveljump Healthcare Corp | PairCorr |
| 0.44 | EDIT | Editas Medicine | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Mesoblast's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Mesoblast Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Mesoblast and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Mesoblast and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Mesoblast does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Mesoblast Stock performing well and Mesoblast Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Mesoblast's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| OCUL | 2.97 | (0.24) | 0.00 | (3.71) | 0.00 | 6.04 | 36.20 | |||
| EWTX | 4.14 | 0.82 | 0.18 | 0.74 | 4.24 | 12.91 | 38.85 | |||
| GLPG | 0.99 | 0.07 | 0.02 | 0.22 | 1.23 | 2.62 | 7.99 | |||
| GPCR | 5.09 | 1.90 | 0.42 | (1.77) | 3.40 | 8.23 | 112.39 | |||
| QURE | 4.07 | (0.35) | 0.00 | (0.48) | 0.00 | 9.37 | 28.69 | |||
| VRDN | 1.96 | 0.35 | 0.16 | 1.01 | 1.69 | 5.57 | 17.41 | |||
| LQDA | 3.10 | 0.83 | 0.21 | 1.28 | 3.29 | 8.00 | 19.63 | |||
| NUVB | 4.10 | 0.29 | 0.06 | 0.33 | 4.66 | 7.33 | 68.61 | |||
| IBRX | 5.20 | 1.71 | 0.35 | 2.26 | 4.25 | 11.16 | 51.87 | |||
| COGT | 4.75 | 1.71 | 0.63 | 0.59 | 2.27 | 5.71 | 126.24 |
Cross Equities Net Income Analysis
Compare Mesoblast and related stocks such as Ocular Therapeutix, Edgewise Therapeutics, and Galapagos NV ADR Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OCUL | (14.1 M) | (14.1 M) | (14.1 M) | (13.3 M) | (28.6 M) | (39.7 M) | (44.7 M) | (63.4 M) | (57.7 M) | (86.4 M) | (155.6 M) | (6.6 M) | (71 M) | (80.7 M) | (193.5 M) | (265.9 M) | (252.6 M) |
| EWTX | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (17.1 M) | (42.1 M) | (15.4 M) | (100.2 M) | (133.8 M) | (120.4 M) | (114.4 M) |
| GLPG | (3.6 M) | (33.1 M) | (5.7 M) | (8.1 M) | 33.2 M | (118.4 M) | 54 M | (115.7 M) | (29.3 M) | 149.8 M | (305.4 M) | (125.4 M) | (218 M) | 211.7 M | 74.1 M | 66.7 M | 70 M |
| GPCR | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (40 M) | (51.3 M) | (89.6 M) | (122.5 M) | (110.3 M) | (104.8 M) |
| QURE | (22.4 M) | (22.4 M) | (19.5 M) | (37 M) | (45 M) | (78.1 M) | (73.4 M) | (80.4 M) | (83.3 M) | (124.2 M) | (125 M) | 329.6 M | (126.8 M) | (308.5 M) | (239.6 M) | (215.6 M) | (204.8 M) |
| VRDN | (7.2 M) | (7.2 M) | (7.2 M) | (2.2 M) | (7.9 M) | (11.3 M) | (12.7 M) | (26.5 M) | (32.7 M) | (41.9 M) | (110.7 M) | (79.4 M) | (129.9 M) | (237.7 M) | (269.9 M) | (243 M) | (230.8 M) |
| LQDA | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (29.2 M) | (53.1 M) | (47.6 M) | (59.8 M) | (34.6 M) | (41 M) | (78.5 M) | (130.4 M) | (117.4 M) | (111.5 M) |
| NUVB | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (33.6 M) | (41.7 M) | (86.8 M) | (104.2 M) | (75.8 M) | (567.9 M) | (511.1 M) | (485.6 M) |
| IBRX | (2 M) | (2 M) | (2 M) | (2 M) | (6.2 M) | (236.9 M) | (120.8 M) | (96.4 M) | (96.2 M) | (65.8 M) | (221.9 M) | (346.8 M) | (416.6 M) | (583.2 M) | (413.6 M) | (372.2 M) | (353.6 M) |
| COGT | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (18.1 M) | (25.5 M) | (34.5 M) | (30.3 M) | (74.8 M) | (72.3 M) | (132.6 M) | (192.4 M) | (255.9 M) | (230.3 M) | (218.8 M) |
Mesoblast and related stocks such as Ocular Therapeutix, Edgewise Therapeutics, and Galapagos NV ADR Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Mesoblast financial statement analysis. It represents the amount of money remaining after all of Mesoblast operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Mesoblast Competitive Analysis
The better you understand Mesoblast competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Mesoblast's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Mesoblast's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Mesoblast Competition Performance Charts
Five steps to successful analysis of Mesoblast Competition
Mesoblast's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Mesoblast in relation to its competition. Mesoblast's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Mesoblast in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Mesoblast's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Mesoblast, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Mesoblast position
In addition to having Mesoblast in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Raw Materials Thematic Idea Now
Raw Materials
Companies that are involved with the development and processing of raw materials such as silver or forestry. The Raw Materials theme has 15 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Raw Materials Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Mesoblast Correlation with its peers. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Will Biotechnology sector continue expanding? Could Mesoblast diversify its offerings? Factors like these will boost the valuation of Mesoblast. Expected growth trajectory for Mesoblast significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mesoblast data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.85) | Revenue Per Share | Quarterly Revenue Growth 4.586 | Return On Assets | Return On Equity |
Investors evaluate Mesoblast using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Mesoblast's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Mesoblast's market price to deviate significantly from intrinsic value.
Understanding that Mesoblast's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mesoblast represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Mesoblast's market price signifies the transaction level at which participants voluntarily complete trades.